Pneumonia, Fungal: Multimedia

References

1. Hung CC, Chang SC. Impact of highly active antiretroviral therapy on incidence and management of human immunodeficiency virus-related opportunistic infections. J Antimicrob Chemother. Nov 2004;54(5):849-53. [Medline].

2. Bochud PY, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med. Oct 23 2008;359(17):1766-77. [Medline].

3. Kesh S, Mensah NY, Peterlongo P, et al. TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation. Ann N Y Acad Sci. Dec 2005;1062:95-103. [Medline].

4. Buchheidt D, Hummel M, Schleiermacher D, Spiess B, Hehlmann R. Current molecular diagnostic approaches to systemic infections with aspergillus species in patients with hematological malignancies. Leuk Lymphoma. Mar 2004;45(3):463-8. [Medline].

5. Herbrecht R, Letscher-Bru V, Oprea C, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol. Apr 1 2002;20(7):1898-906. [Medline].

6. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis. Jun 2004;4(6):349-57. [Medline].

7. Musher B, Fredricks D, Leisenring W, Balajee SA, Smith C, Marr KA. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol. Dec 2004;42(12):5517-22. [Medline].

8. Maertens JA, Klont R, Masson C, et al. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis. May 15 2007;44(10):1329-36. [Medline].

9. Penack O, Rempf P, Graf B, Blau IW, Thiel E. Aspergillus galactomannan testing in patients with long-term neutropenia: implications for clinical management. Ann Oncol. May 2008;19(5):984-9. [Medline].

10. Viscoli C, Machetti M, Cappellano P, et al. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis. Mar 15 2004;38(6):913-6. [Medline].

11. Del Bono V, Mikulska M, Viscoli C. Invasive aspergillosis: diagnosis, prophylaxis and treatment. Curr Opin Hematol. Nov 2008;15(6):586-93. [Medline].

12. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. Feb 1 2007;44(3):373-9. [Medline].

13. Mussini C, Pezzotti P, Miro JM, et al. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin Infect Dis. Feb 15 2004;38(4):565-71. [Medline].

14. Kaffarnik M, Utzolino S, Blaich A, Hopt UT. Successful multimodal therapy of invasive pulmonary and central nervous system aspergillosis in a neutropenic surgical patient: case report and review of the literature. Mycoses. Jan 2008;51(1):74-8. [Medline].

15. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. Mar 1 2002;34(5):563-71. [Medline].

16. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. Aug 8 2002;347(6):408-15. [Medline].

17. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. Mar 1 2003;36(5):630-7. [Medline].

18. Benjamin DK Jr, Driscoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother. Feb 2006;50(2):632-8. [Medline].

19. [Best Evidence] Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. Jun 14 2007;356(24):2472-82. [Medline].

20. Turner MS, Drew RH, Perfect JR. Emerging echinocandins for treatment of invasive fungal infections. Expert Opin Emerg Drugs. May 2006;11(2):231-50. [Medline].

21. [Guideline] Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. Feb 1 2008;46(3):327-60. [Medline].

22. Hamza NS, Ghannoum MA, Lazarus HM. Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. Sep 2004;34(5):377-89. [Medline].

23. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. Jan 25 2007;356(4):335-47. [Medline].

24. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. Jan 25 2007;356(4):348-59. [Medline].

25. Avery RK. Aspergillosis in hematopoietic stem cell transplant recipients: risk factors, prophylaxis, and treatment. Curr Infect Dis Rep. May 2009;11(3):223-8. [Medline].

26. Catanzaro A. Fungal pneumonias. Curr Opin Pulm Med. Mar 1997;3(2):146-50. [Medline].

27. Conces DJ Jr. Endemic fungal pneumonia in immunocompromised patients. J Thorac Imaging. Jan 1999;14(1):1-8. [Medline].

28. Connolly JE Jr, McAdams HP, Erasmus JJ, Rosado-de-Christenson ML. Opportunistic fungal pneumonia. J Thorac Imaging. Jan 1999;14(1):51-62. [Medline].

29. Crawford SW. Respiratory Disease in Bone Marrow and Hematopoietic Stem Cell Transplantation. In: Fishman AP, ed. Fishman's Pulmonary Diseases and Disorders. Vol. 2. 3^rd ed. New York, NY: McGraw-Hill; 1998:2147-8.

30. Fishman JA. Pulmonary infections in Neutropenia and Cancer. In: Fishman AP, ed. Fishman's Pulmonary Diseases and Disorders. Vol. 2. 3^rd ed. New York, NY: McGraw-Hill; 1998:2124-6.

31. Fishman JA. HIV Infection and Opportunistic Pulmonary Infections in AIDS. In: Fishman AP, ed. Fishman's Pulmonary Diseases and Disorders. Vol. 2. 3^rd ed. New York, NY: McGraw-Hill; 1998:2114-5.

32. Goldman M, Wheat LJ. Cryptococcal Infections. In: Fishman AP, ed. Fishman's Pulmonary Diseases and Disorders. Vol 2. 3^rd ed. New York, NY: McGraw-Hill; 1998:2305-12.

33. Larone DH, Mitchell TG, Walsh TJ. Histoplasma, Blastomyces, Coccidioided, and other Dimorphic Fungi causing systemic Mycoses. In: Murray PR, ed. Manual of Clinical Microbiology. 7^th ed. Washington DC: ASM Press; 1999:1259-74.

34. Lass-Flörl C, Gunsilius E, Gastl G, Freund M, Dierich MP, Petzer A. Clinical evaluation of Aspergillus-PCR for detection of invasive aspergillosis in immunosuppressed patients. Mycoses. 2005;48 Suppl 1:12-7. [Medline].

35. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. Dec 1 2004;39(11):1563-71. [Medline].

36. Pound MW, Drew RH, Perfect JR. Recent advances in the epidemiology, prevention, diagnosis, and treatment of fungal pneumonia. Curr Opin Infect Dis. Apr 2002;15(2):183-94. [Medline].

37. Rickerts V, Bialek R, Tintelnot K, Jacobi V, Just-Nubling G. Rapid PCR-based diagnosis of disseminated histoplasmosis in an AIDS patient. Eur J Clin Microbiol Infect Dis. Nov 2002;21(11):821-3. [Medline].

38. Sarosi GA. Cryptococcal pneumonia. Semin Respir Infect. Mar 1997;12(1):50-3. [Medline].

39. Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med. Apr 1 2006;173(7):707-17. [Medline].

40. Sugar AM, Olek EA. Aspergillus syndromes, Mucormycosis, and Pulmonary Candidiasis. In: Fishman AP, ed. Fishman's Pulmonary Diseases and Disorders. Vol. 2. 3^rd ed. New York, NY: McGraw-Hill; 1998:2265-87.

41. Wheat LJ. Endemic Mycoses of North America: Histoplasmosis, Coccidioidomycosis, and Blastomycosis. In: Fishman AP, ed. Fishman's Pulmonary Diseases and Disorders. Vol. 2. 3^rd ed. New York, NY: McGraw-Hill; 1999:2289-2303.

42. White PL, Archer AE, Barnes RA. Comparison of non-culture-based methods for detection of systemic fungal infections, with an emphasis on invasive Candida infections. J Clin Microbiol. May 2005;43(5):2181-7. [Medline].

43. Won HJ, Lee KS, Cheon JE, et al. Invasive pulmonary aspergillosis: prediction at thin-section CT in patients with neutropenia--a prospective study. Radiology. Sep 1998;208(3):777-82. [Medline].

44. Worthy SA, Flint JD, Muller NL. Pulmonary complications after bone marrow transplantation: high-resolution CT and pathologic findings. Radiographics. Nov-Dec 1997;17(6):1359-71. [Medline].

45. Yamada H, Kotaki H, Takahashi T. Recommendations for the treatment of fungal pneumonias. Expert Opin Pharmacother. Aug 2003;4(8):1241-58. [Medline].

Further Reading

Keywords

fungal pneumonia, pulmonary mycosis, mycotic pneumonia, , endemic fungal pneumonia, aspergillosis, meningoencephalitis, cryptococcosis, acute leukemia, lymphoma, myeloablative chemotherapy, bone marrow transplantation, peripheral blood stem cell transplantation, allogeneic stem cell transplantation, unrelated donor transplantation, graft-versus-host disease, graft versus host disease, solid organ transplantation on immunosuppressive treatment, prolonged corticosteroid therapy, AIDS, congenital immune deficiency syndromes

Contributor Information and Disclosures

Author

Romeo A Mandanas, MD, FACP, Director, Western Oklahoma Blood and Marrow Transplant Program, Site Research Leader, Cancer Care Associates-Oklahoma City
Romeo A Mandanas, MD, FACP is a member of the following medical societies: American College of Physicians, American Medical Association, American Society for Blood and Marrow Transplantation, American Society of Clinical Oncology, American Society of Hematology, and Oklahoma State Medical Association
Disclosure: Nothing to disclose.

Medical Editor

Ryland P Byrd Jr, MD, Professor, Department of Internal Medicine, Division of Pulmonary Medicine and Critical Care Medicine, James H Quillen College of Medicine, East Tennessee State University; Chief of Pulmonary Medicine, Medical Director of Respiratory Therapy, Intensive Care Unit, Program Director of Pulmonary Diseases and Critical Care Medicine Fellowship, James H Quillen Veterans Affairs Medical Center
Ryland P Byrd Jr, MD is a member of the following medical societies: American College of Chest Physicians, American Thoracic Society, and Southern Medical Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Om Prakash Sharma, MD, FRCP, FCCP, DTM&H, Professor, Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Southern California Keck School of Medicine
Om Prakash Sharma, MD, FRCP, FCCP, DTM&H is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American College of Chest Physicians, American College of Physicians, American Federation for Medical Research, American Osler Society, American Thoracic Society, New York Academy of Medicine, and Royal Society of Medicine
Disclosure: Keck School of Medicine, USC None None

CME Editor

Timothy D Rice, MD, Associate Professor, Departments of Internal Medicine and Pediatrics and Adolescent Medicine, Saint Louis University School of Medicine
Timothy D Rice, MD is a member of the following medical societies: American Academy of Pediatrics and American College of Physicians
Disclosure: Nothing to disclose.

Chief Editor

Zab Mosenifar, MD, Director, Division of Pulmonary and Critical Care Medicine, Director, Women's Guild Pulmonary Disease Institute, Executive Vice Chair, Department of Medicine, Cedars Sinai Medical Center; Professor of Medicine, David Geffen School of Medicine at UCLA
Zab Mosenifar, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Federation for Medical Research, and American Thoracic Society
Disclosure: Nothing to disclose.